Loading
ICU Medical Inc/de Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Aug 2025.
ICU Medical Inc/de: what insiders have been doing
ICU Medical Inc/de, founded in 1984, is a Healthcare & Pharma company based in San Clemente, United States. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 39 filings came from 16 insiders.
There is no open-market purchase to report; the filings show 16 sales worth €6.5M by 6 insiders. The largest single trade was a sale of €1.4M by Voigtlander Christian B., published on 11 August 2026, equal to 0.039% of the market capitalisation.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 39 filings here. Over the whole record (from 2016), the tally stands at 3 purchases and 56 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.23 bn USD and net income at 732,000 USD.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
193
Thresholds
n/a
Buy Volume
€1M
3 ops. · all time
Sell Volume
€96M
56 ops. · all time
Who traded when
BuySaleVirginia Ruth Sanzone7 sales
Brian Michael Bonnell5 sales
Christian B. Voigtlander3 sales
Daniel Woolson3 sales
Ben Sousa2 sales
Elisha W. Finney2 sales
+2 other insiders
Since the insiders bought
- +37.8%Entry US$127.04 · Close at T+365 US$175.10
- +50.9%Entry US$120.95 · Close at T+365 US$182.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,114 of 24,148 companies
34.7
score / 100
Value36
Quality34
FCF yld2.0%
Earn yld0.0%
EV/EBITDA18.1x
ROE1.4%
Gross mgn37%
Net mgn0.0%
Debt/EBITDA4.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$162.69
Analyst consensus
8 analysts1.63/5
US$178.00Target US$193.38(+19%)US$210.00
Income statement
RevenueUS$2.2B
Gross profitUS$822M37% margin
EBITDAUS$298.4M13% margin
Net incomeUS$732k1.4% margin
Valuation
PER (trailing)136.7x
PER (forward)16.9x
P/Book1.9x
Beta0.87
Balance sheet & cash
Market capUS$4.1B
Total debtUS$1.3B
Free Cash FlowUS$82.8M
Debt / Equity60%
Profitability & ownership
ROE1.4%
ROA1.9%
% insiders1.8%
% institutions115.8%
Last declaration on 3 September 2026
Declarations193 total
4,856 shares@ US$168.68830.050% mcap100.0% of flowCommonSEC144:0001950047-26-009050
1,238 shares@ US$168.43520.0050% mcap13.5% of flowCommon StockSEC:0001669639-26-000004:1
724 shares@ US$169.52550.0029% mcap7.9% of flowCommon StockSEC:0001669639-26-000004:2
692 shares@ US$171.5150.0029% mcap7.7% of flowCommon StockSEC:0001669639-26-000004:3
2,202 shares@ US$167.6670.0089% mcap23.8% of flowCommon StockSEC:0001669639-26-000004:0
6,381 shares@ US$175.000.027% mcap40.9% of flowCommon StockSEC:0001804831-26-000006:0
9,307 shares@ US$172.78850.097% mcap100.0% of flowCommonSEC144:0001950047-26-008855
1,914 shares@ US$172.12260.0079% mcap12.1% of flowCommon StockSEC:0001804831-26-000005:1
4,568 shares@ US$173.44370.019% mcap29.1% of flowCommon StockSEC:0001804831-26-000005:2
1,712 shares@ US$171.05320.0070% mcap10.8% of flowCommon StockSEC:0001804831-26-000005:0
1,113 shares@ US$173.91440.0047% mcap7.1% of flowCommon StockSEC:0001804831-26-000005:3
5,417 shares@ US$181.330.060% mcap100.0% of flowCommonSEC144:0001950047-26-008063
5,417 shares@ US$181.330.024% mcap34.6% of flowCommon StockSEC:0001698998-26-000004:0
2,250 shares@ US$178.31520.024% mcap100.0% of flowCommonSEC144:0001950047-26-008014
378 shares@ US$182.48170.0042% mcap100.0% of flowCommonSEC144:0001950047-26-007934
8,929 shares@ US$182.93240.099% mcap100.0% of flowCommonSEC144:0001950047-26-007972
378 shares@ US$182.48180.0017% mcap19.1% of flowCommon StockSEC:0001217439-26-000002:0
8,929 shares@ US$182.93250.039% mcap17.3% of flowCommon StockSEC:0001727477-26-000003:0
2,447 shares@ US$124.080.0067% mcap44.9% of flowCommon StockSEC:0001669639-26-000003:0
1,254 shares0Common StockSEC:0001871884-26-000001:0
1,254 shares0Common StockSEC:0001534342-26-000008:0
2,424 shares@ US$101.060.0053% mcap100.0% of flowCommon StockSEC:0001645866-26-000001:0
704 shares0Common StockSEC:0001534342-26-000007:0
25 of 193 declarations
About ICU Medical Inc/de
ICU Medical, Inc. (Nasdaq: ICUI) is a U.S.-based medical technology company focused on infusion therapy, vascular access, and critical care applications. The company is listed on the NASDAQ market in the United States, was founded in 1984, and is headquartered in San Clemente, California. For international investors, the company sits in a specialized but essential part of the healthcare supply chain: its devices are used daily in hospitals and other care settings for IV therapy, medication safety, monitoring, and selected critical care workflows. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398426000008/icui-20251231.htm?utm_source=openai))
ICU Medical built its franchise first around infusion-related products and then expanded through internal development and acquisitions. Key milestones include the purchase of Hospira Infusion Systems, which broadened the company’s pump and consumables portfolio, and later the Smiths Medical acquisition, which added syringe and ambulatory infusion devices, vascular access products, and vital care offerings. More recently, ICU Medical restructured part of its portfolio through a joint venture with Otsuka Pharmaceutical Factory around the IV Solutions business, aimed at improving manufacturing capability and sharpening the company’s long-term operating profile. ([ir.icumed.com](https://ir.icumed.com/news-releases/news-release-details/icu-medical-inc-acquire-hospira-infusion-systems-business-pfizer?utm_source=openai))
Read moreShow less
From a business-model perspective, ICU Medical is best understood as an integrated platform in infusion and adjacent clinical areas. Its portfolio includes IV smart pumps, infusion sets, needlefree connectors, peripheral IV catheters, sterile IV solutions, closed-system transfer devices for hazardous drugs, pharmacy compounding systems, and a range of respiratory, anesthesia, patient monitoring, and temperature-management products. The company also sells certain products on an OEM basis to other medical-device manufacturers. This breadth gives ICU Medical meaningful exposure across acute care, alternative-site care, and, in some cases, home-care settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398426000008/icui-20251231.htm?utm_source=openai))
In competitive terms, ICU Medical is often framed as a “pure-play” infusion leader with a broader global footprint than in its early years. Its competitive strengths come from the breadth of its offering, technical depth in consumables, clinical safety features, and long-standing customer relationships with hospitals and healthcare systems. The company’s geographic reach has expanded materially through acquisitions, with sales and operations spanning the United States and international markets. ([ir.icumed.com](https://ir.icumed.com/news-releases/news-release-details/icu-medical-completes-acquisition-hospira-infusion-systems?utm_source=openai))
Recent developments have centered on portfolio integration and operating improvement. In 2025 and 2026, management highlighted continued Smiths Medical integration work, the formation of the IV Solutions joint venture with Otsuka, and a focus on organic growth, manufacturing execution, and capital discipline. The company also released fourth-quarter 2025 results and 2026 guidance in early 2026, underscoring that ICU Medical remains in a multi-year transformation phase following major portfolio reshaping. For equity investors, that makes the story a combination of defensive healthcare exposure and an execution-focused industrial turnaround within medical technology. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398426000008/icui-20251231.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
